Drug
cedazuridine and decitabine
Marketed as INQOVI.
Generic name
cedazuridine and decitabine
Brand names
INQOVI
First FDA approval
2020-07-07
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| NDA212576 | INQOVI | 2020-07-07 | TAIHO ONCOLOGY |
Manufacturers
TAIHO ONCOLOGY
Frequently asked questions
When was cedazuridine and decitabine FDA approved?
Earliest FDA approval on record: 2020-07-07.
What brand names are sold as cedazuridine and decitabine?
INQOVI.
Sources
Appeal a cedazuridine and decitabine denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com